Publications

Featured Publications

Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Future Oncology

calendar icon June 2023


>> View Article

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

  • Reset Filters

Assessment of Safety and Immunologic Activity of Nemvaleukin Alfa in Patients With Advanced Solid Tumors Treated With Less Frequent Intravenous Dosing (ARTISTRY-3)

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

Subcutaneous Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Refractory Solid Tumors (ARTISTRY-2)

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

Preliminary Pharmacodynamic Characterization in Patients With Platinum-Resistant Ovarian Cancer Treated With Nemvaleukin in Combination With Pembrolizumab

American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer

calendar icon October 2023


>> View Poster

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Future Oncology

calendar icon June 2023


>> View Article

ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2023


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2023


>> View Poster

A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2023


>> View Poster

A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2023


>> View Poster

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

European Congress on Gynaecological Oncology (ESGO) Congress

calendar icon October 2022


>> View Poster

Using Low Dose and Intermediate-affinity IL-2 receptor agonist (Nemvaleukin alfa) with XRT to address PD1 Resistance

American Society for Therapeutic Radiology and Oncology ( ASTRO) Annual Meeting

calendar icon October 2022


>> View Presentation

ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2022


>> View Poster